U.S. Semiconductors Stock News

NasdaqGM:INOD
NasdaqGM:INODProfessional Services

Is Innodata’s 2026 AI‑Driven Growth Outlook Altering The Investment Case For Innodata (INOD)?

In February 2026, Innodata Inc. reported fourth-quarter 2025 sales of US$72.38 million versus US$59.18 million a year earlier, with quarterly net income easing to US$8.83 million from US$10.30 million, while full-year 2025 sales increased to US$251.66 million and net income to US$32.18 million. Alongside these results, management projected approximately 35% or more revenue growth for 2026 as AI-related programs scale, underscoring how Innodata is tying its business more closely to the...
NasdaqGS:NFLX
NasdaqGS:NFLXEntertainment

Netflix Uses Ben Affleck AI Startup To Sharpen Production And Investor Focus

Netflix (NasdaqGS:NFLX) has acquired AI filmmaking startup InterPositive, founded by Ben Affleck. The deal brings InterPositive’s AI tools in house to support Netflix’s post production and creative workflows. Netflix is using breakup fee proceeds to fund the move, reflecting a focus on long term content technology. For you as an investor, this deal sits at the intersection of content and software, which has been an area of interest across the streaming space. Netflix already operates as a...
NasdaqGS:LKFN
NasdaqGS:LKFNBanks

Lakeland Financial (LKFN) Valuation Check After Board Doubles Share Repurchase Authorization

Lakeland Financial (LKFN) recently caught investor attention after its board doubled the company’s common stock repurchase authorization to US$60 million, a move that reshapes how management can return capital to shareholders. See our latest analysis for Lakeland Financial. The repurchase expansion comes after a stretch where the 30 day share price return of 9.17% and 7 day return of 3.05% sit alongside a 1 year total shareholder return of 3.3%. Together, these figures point to relatively...
NasdaqCM:ONDS
NasdaqCM:ONDSCommunications

Ondas (ONDS) Is Down 7.9% After New Defense Orders And Border Security Deal - What's Changed

In recent months, Ondas Holdings has announced roughly US$6,000,000 in new counter-drone orders, a US$20,000,000 autonomous border security purchase order, and a US$10,000,000 investment in World View Enterprises to co-develop stratospheric intelligence and surveillance solutions for government and critical infrastructure customers. Together with a planned merger with Mistral Inc. to gain U.S. prime contractor access, these moves deepen Ondas’ role in autonomous defense, border protection,...
NasdaqGS:BEAM
NasdaqGS:BEAMBiotechs

Beam Therapeutics (BEAM) Leverages New Financing And IP Control Is Its Gene-Editing Edge Strengthening?

Beam Therapeutics recently reported a swing to fourth-quarter 2025 net income of US$244.3 million and entered a long-term, up-to-US$500 million credit facility with Sixth Street to support its sickle cell gene-editing candidate, while also filing a US$144.13 million shelf registration tied to an employee stock plan. At the same time, Beam preserved exclusive access to core base-editing intellectual property through a direct Kobe University license after ending its cross-license with Bio...
NYSE:ENOV
NYSE:ENOVMedical Equipment

A Look At Enovis (ENOV) Valuation After 2025 Earnings Losses And 2026 Revenue Guidance

Why Enovis stock is back in focus after its latest results Enovis (ENOV) has come back onto investors’ radar after reporting fourth quarter and full year 2025 results that combined continued net losses, sizeable goodwill impairment charges, and fresh 2026 revenue guidance. See our latest analysis for Enovis. Following the earnings release and goodwill impairment news on 26 February, Enovis’ share price has seen a 1 day share price return of 0.78% and a 1 month share price return of 8.5%...
NYSE:AD
NYSE:ADWireless Telecom

The Bull Case For Array Digital Infrastructure (AD) Could Change Following New Flagship Device Bundles From Major Carriers – Learn Why

In late February and early March 2026, T-Mobile and UScellular announced they would offer Apple’s new iPhone 17e and iPad Air, alongside Samsung’s Galaxy S26 series, all promoted with rich service bundles and perks that encourage heavier data usage and broader device adoption. For Array Digital Infrastructure, these client device launches point to potentially higher network traffic and capacity requirements, which could increase demand for its infrastructure and services over time. Next,...
NasdaqGS:PGNY
NasdaqGS:PGNYHealthcare

Assessing Progyny (PGNY) Valuation After Strong 2025 Results And A Cautious 2026 Outlook

Why Progyny stock is back on investors’ radar Progyny (PGNY) is drawing fresh attention after reporting fourth quarter and full year 2025 earnings, pairing that update with a completed share buyback, cautious 2026 revenue guidance, and a new ESOP related shelf registration. See our latest analysis for Progyny. Progyny’s recent earnings update, buyback completion, and ESOP related shelf registration have arrived against a weak share price backdrop, with a 30 day share price return of 16.58%...
NasdaqGS:AAPL
NasdaqGS:AAPLTech

Assessing Apple (AAPL) Valuation As Tariffs And Supply Chain Shifts Pressure The Outlook

Apple (AAPL) continues to draw attention as investors weigh its recent share performance against the company’s scale, with annual revenue of about US$435.6b and net income near US$117.8b. See our latest analysis for Apple. At a latest share price of US$257.46, Apple’s recent 1 month share price return of 7.43% and year to date share price return of 5.00% contrast with a 1 year total shareholder return of 13.67%. This sits alongside very strong 3 year and 5 year total shareholder returns of...
NasdaqGS:APLS
NasdaqGS:APLSBiotechs

Assessing Apellis Pharmaceuticals (APLS) Valuation As Long Term Returns Lag And P/E Diverges From Biotech Peers

Recent performance context for Apellis Pharmaceuticals (APLS) With no single headline event driving recent trading, investors looking at Apellis Pharmaceuticals (APLS) today are weighing a commercial stage biotech that reports revenue of US$1,003.8m and net income of US$22.4m. See our latest analysis for Apellis Pharmaceuticals. At a share price of US$20.07, Apellis Pharmaceuticals has a 1 month share price return of 14.6% and a year to date share price decline of 22.4%. The 1 year total...
NasdaqGS:HWC
NasdaqGS:HWCBanks

Assessing Hancock Whitney (HWC) Valuation After Recent Share Price Weakness

Hancock Whitney (HWC) has drawn investor attention following recent share price weakness, with the stock declining 3.2% over the past day and 15.5% over the past month. See our latest analysis for Hancock Whitney. Despite the recent setback, the latest 30 day share price return of a 15.5% decline and a softer year to date share price return sit alongside a 1 year total shareholder return of 28.3%. This suggests earlier momentum has cooled, even though longer term holders remain ahead. If the...
NYSE:CRGY
NYSE:CRGYOil and Gas

Does Crescent Energy’s New Convertible Notes And ESOP Shift Change The Bull Case For CRGY?

Crescent Energy recently completed a US$600 million Rule 144A offering of 2.75% senior unsecured convertible notes due March 15, 2031, alongside filing a US$12.12 million shelf registration for 1,035,228 Class A shares tied to its ESOP. These capital moves follow a shift from a full-year net loss to US$132.91 million in net income in 2025, highlighting greater financial flexibility and evolving employee ownership. We’ll now examine how the new US$600 million convertible notes may influence...
NYSE:GS
NYSE:GSCapital Markets

Will Goldman Sachs’ (GS) Expanded Bond Issuance Amid Geopolitical Strains Change Its Risk Narrative?

In late February and early March 2026, The Goldman Sachs Group, Inc. issued a wide range of new bonds and notes, from short-dated floating-rate instruments to long-dated callable senior unsecured debt, as part of its ongoing use of shelf registrations to access funding and refine its capital structure. At the same time, rising geopolitical tensions, higher oil prices and concerns over inflation and private credit risks have amplified risk perceptions around large investment banks like...
NasdaqCM:AHCO
NasdaqCM:AHCOHealthcare

A Look At AdaptHealth (AHCO) Valuation After Loss-Making 2025 Results And Goodwill Impairment

Why AdaptHealth’s latest results matter for investors AdaptHealth (AHCO) recently reported full year 2025 results that shifted from profit to a net loss, alongside a sizeable goodwill impairment and fresh 2026 revenue guidance. This gives investors several moving pieces to assess. For 2025, AdaptHealth reported sales of US$3.24b compared with US$3.26b a year earlier, while net income swung to a loss of US$70.79m from net income of US$90.42m in the prior year. The company also recorded an...
NasdaqGS:CHTR
NasdaqGS:CHTRMedia

What Charter Communications (CHTR)'s New COO Appointment Means For Shareholders

In late February 2026, Charter Communications appointed veteran telecom executive Nick Jeffery as Chief Operating Officer, tasking him with leading Marketing and Sales, Field Operations and Customer Operations across Spectrum’s residential and business services from September 1, 2026. Jeffery’s track record of operational overhauls and customer satisfaction gains at Frontier Communications and Vodafone UK signals a meaningful shift in how Charter may approach service quality and execution...
NYSE:HP
NYSE:HPEnergy Services

Should Helmerich & Payne’s Earnings Miss and Impairment Charge Require Action From HP Investors?

In early March 2026, Helmerich & Payne reported a first-quarter fiscal 2026 adjusted net loss that missed analyst expectations, driven by weakness in its North America Solutions segment and a sizeable non-cash impairment charge, even as international operations supported revenue. At the same time, the company continued returning cash to investors through a US$0.25 per-share quarterly dividend and advanced debt reduction plans, highlighting a focus on capital discipline despite operating...
NasdaqGS:TW
NasdaqGS:TWCapital Markets

Evaluating Tradeweb Markets (TW) Valuation As Recent Share Gains Contrast With Mixed Longer Term Returns

Recent performance snapshot With no single news headline driving attention today, Tradeweb Markets (TW) is drawing interest after a recent share price of $124.59 and a mixed return picture, including a 17.3% gain year to date alongside a 6% decline over the past year. See our latest analysis for Tradeweb Markets. Recent trading has been positive, with a 30 day share price return of 11.11% and a year to date share price return of 17.32%, set against a 1 year total shareholder return decline of...
NasdaqGS:CHRD
NasdaqGS:CHRDOil and Gas

Chord Energy (CHRD) Is Up 7.1% After Highlighting Lower Costs And Shareholder Returns Has The Bull Case Changed?

In late February 2026, Chord Energy reported Q4 2025 revenue of US$1,169.44 million and net income of US$84.42 million, alongside updated production guidance, a US$1.30 per-share base dividend declaration, and a completed US$47.83 million buyback tranche. An interesting angle is that management highlighted materially lower finding and development costs and projected US$700 million in 2026 free cash flow, after having returned US$6.70 billions to shareholders since 2021. We’ll now examine how...
NasdaqGS:INDV
NasdaqGS:INDVPharmaceuticals

Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Earnings Growth And New US$400 Million Buyback

Why Indivior Pharmaceuticals Stock Is Back on Investors’ Radar Indivior Pharmaceuticals (INDV) recently reported higher earnings for 2025, reaffirmed its 2026 revenue guidance of US$1,125 million to US$1,195 million, and announced a new US$400 million share repurchase plan. See our latest analysis for Indivior Pharmaceuticals. Despite the strong earnings update and US$400 million buyback news, the share price has had a 30 day share price return of a 6.08% decline and a 90 day share price...
NasdaqGS:FROG
NasdaqGS:FROGSoftware

JFrog (FROG) Valuation Check After Sector Sentiment Shift And Insider Stock Sales

JFrog (FROG) has been back in focus after a sharp swing, driven first by executive stock sales and then by a rebound tied to stronger sector sentiment following Broadcom’s upbeat AI related revenue outlook. See our latest analysis for JFrog. Those swings sit against a weaker recent trend, with a 30 day share price return of 15.42% and a 90 day share price return of 41.03%. This is the case even though the 1 year total shareholder return is 20.91% and the 3 year total shareholder return is...
NYSE:SCCO
NYSE:SCCOMetals and Mining

Why Southern Copper (SCCO) Is Down 15.5% After China Demand Jitters And Analyst Downgrades - And What's Next

In early March 2026, Southern Copper faced renewed pressure as analyst downgrades, softer copper prices tied to China’s lower growth target, a stronger US dollar, and geopolitical tensions all weighed on sentiment despite previously strong quarterly earnings. Adding to the uncertainty, insider share sales and unusually active, mixed options positioning by large investors highlighted growing debate over the company’s near-term outlook. Next, we’ll explore how this wave of downgrades and...
NasdaqGS:NTRS
NasdaqGS:NTRSCapital Markets

Does Northern Trust's New CK Capital Mandate and CLO Upgrades Reveal a Sharper Strategy for NTRS?

In early March 2026, Northern Trust announced it had been appointed to provide fund administration, global custody, financial reporting and transfer agency services to Netherlands-based CK Capital Partners’ CK Capital Value Fund Cooperatief U.A., alongside expanding its CLO middle-office capabilities and adding Berenberg’s AI-driven models to its dynamic currency hedging framework. These developments highlight Northern Trust’s push to deepen its role in complex asset servicing and risk...
NasdaqCM:LIND
NasdaqCM:LINDHospitality

Lindblad Expeditions Holdings (LIND) Valuation Check After Recent Share Price Volatility

Recent performance snapshot for Lindblad Expeditions Holdings (LIND) Lindblad Expeditions Holdings (LIND) has drawn attention after recent share price swings, with a 2% decline over the past day and an 8% move lower over the past week catching investor eyes. Over the past month the stock shows an 11% decline, while the past 3 months reflect a 42.6% total return. This sets up a contrasting short term and medium term performance picture that investors may want to unpack. See our latest analysis...
NasdaqCM:SLNO
NasdaqCM:SLNOBiotechs

Is Soleno’s Profit Swing and New CFO Hire Altering The Investment Case For Soleno Therapeutics (SLNO)?

In late February 2026, Soleno Therapeutics reported that it moved from a US$55.98 million quarterly loss to a US$43.36 million quarterly profit and filed an approximately US$81.90 million shelf registration for over 2.09 million common shares tied to an employee stock ownership plan. The company also announced a CFO transition, bringing in experienced pharma and capital markets executive Jennifer Fulk just as Soleno’s earnings profile and capital structure are evolving. We’ll now examine how...